Clinical trials located in

Bad Bentheim

Bad Bentheim city is located in Germany. Currently, 13 clinical trials are being conducted in this city.

Bad Bentheim, nestled in Lower Saxony, Germany, is renowned for its medieval castle, Burg Bentheim, which towers over the town, offering a glimpse into its rich history. This city, close to the Dutch border, is steeped in spa culture, thanks to its natural saltwater springs, which have been therapeutic attractions since the 18th century. The Sandstone Museum highlights the local quarrying of Bentheim sandstone, used in landmarks across Europe. Additionally, Bad Bentheim’s picturesque landscapes are crisscrossed by cycling and hiking trails, showcasing the region’s natural beauty.

  • CT-EU-00054021

    Improving psoriasis treatment for patients: a study on brodalumab

    This detailed study focuses on individuals with moderate-to-severe plaque psoriasis who weigh more than 120 kg. It aims to find out if adjusting the dose of the medication brodalumab can lead to better skin health. In this study, participants receive either an adjusted higher dose of brodalumab or the standard dose. Researchers closely monitor the skin’s response to the treatment, checking if the adjusted dose leads to better skin clearance, meaning fewer or no psoriasis symptoms.

    BelgiumCzechiaFranceGermanyGreeceHungaryItalyNetherlandsPolandSpainUnited Kingdom
  • Study on ruxolitinib cream for hand eczema

    This study investigates the use of ruxolitinib cream for adults with chronic hand eczema, a skin condition causing itchy, red, and cracked skin on the hands. The cream is applied directly to the affected areas twice daily for 16 weeks. Participants in the study, who are adults with moderate to severe hand eczema, are either given ruxolitinib cream or a placebo cream. After 16 weeks, all participants can choose to continue with ruxolitinib cream for another 16 weeks. The study aims to find out if this cream can effectively reduce the symptoms of hand eczema, like itchiness and skin pain, and improve overall skin condition and quality of life. Around 180 people are taking part in this study, which doesn’t include healthy volunteers​.

    GermanyPoland
  • Study testing Ruxolitinib cream for Prurigo Nodularis treatment

    This study is testing a cream with Ruxolitinib to see if it’s safe and effective for people with a skin condition called Prurigo Nodularis (PN). The study has three main parts. In the first 12 weeks, participants will receive either the cream with Ruxolitinib or placebo (also known as vehicle-controlled) treatment. After that, all participants will receive the cream with Ruxolitinib for another 40 weeks. After that, there will be an extra 30 days to keep an eye on safety. The trial will measure success by checking if the cream can reduce itchiness. Treatment success will be evaluated by medical professionals, considering factors such as the number of skin nodules and the extent of redness and crusting in the condition’s severity.

    BelgiumFranceGermanyItalyNetherlandsPolandSpain
  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    AustriaCzechiaFranceItalyRomaniaSpainUnited Kingdom
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    AustriaBelgiumFrancePolandUnited Kingdom
  • Discovering a new drug for atopic dermatitis

    This clinical trial aims to evaluate the safety and effectiveness of LEO 138559, a new medication for adults with moderate-to-severe atopic dermatitis, a challenging skin condition. The study tests four different doses of LEO 138559 against a placebo (a treatment without the active drug) over 36 weeks. Participants, who will be randomly assigned to one of the doses or placebo, will receive injections just under the skin at regular clinic visits. The trial includes a 4-week screening phase, a 16-week treatment phase, and a 16-week follow-up. Participants will visit the clinic 17 times and keep a daily electronic diary to track their skin condition and quality of life. This study is crucial for understanding how well LEO 138559 works and its safety in treating this persistent skin condition.

    CzechiaFranceGermanyPolandRomaniaSpainUnited Kingdom
  • Investigating lebrikizumab’s safety for severe Atopic Dermatitis patients

    This study investigates the long-term use of Lebrikizumab in adults and teenagers with atopic dermatitis, a serious skin condition. The focus is on determining the safety and effectiveness of Lebrikizumab over a two-year period. Participants who have completed a previous program may join this extension study. The effectiveness of the treatment is measured using several methods, including the EASI score for assessing the severity of the condition, the IGA scale for rating severity, and a scale for measuring itchiness. Additionally, the extent of body coverage by atopic dermatitis is evaluated. Participants are also required to complete a questionnaire about the impact of the skin condition on their daily life.

    GermanyPoland
  • Exploring the efficacy and safety of new drug in Psoriasis Treatment

    This clinical trial is for patients suffering from a skin condition called mild to moderate psoriasis. The aim of the study is to check the effectiveness and safety of a new drug called HRO350. HRO350 is a soft capsule containing oil extracted from herring roe (fish roe). This oil contains natural substances called phospholipids, which are rich in certain fatty acids. These substances have the potential to slow or stop the inflammation that causes psoriasis. Patients in the study will take HRO350 capsules or a placebo (a dummy medicine that contains no active substance) every day for up to a year. They will also have an 8-week follow-up period after completing treatment. Approximately 519 patients will participate in the study. The test will involve regular check-ups, including blood and urine tests, and an assessment of the severity of patients’ psoriasis.

    FinlandGermanyNorwayPolandUnited Kingdom
  • Long-term safety & effectiveness of rocatinlimab for atopic dermatitis

    This trial is all about studying a medicine called rocatinlimab for grown-ups and teens with a serious skin disease named atopic dermatitis (AD). The main goal is to see if rocatinlimab is safe and can help over a long period. The research will also check how well people tolerate the medication. The focus is on those who previously benefitted from the medicine, showing an improvement on a scoring system that measures itching levels. This trial falls in the third phase, making it crucial towards verifying the effectiveness and monitoring any adverse effects of the drug.

    AustriaCzechiaDenmarkFranceGermanyGreeceHungaryPolandPortugalSlovakiaSpain
  • Study of new drugs in acute lymphoblastic leukemia

    This clinical trial focuses on improving treatment strategies for acute lymphoblastic leukemia (ALL) in a diverse age group, from infants to young adults up to 45 years old. The study combines standard treatments with new drugs, for example, Inotuzumab Ozogamicin and Blinatumomab. The trial aims to tailor treatment to individual patient needs and reduce toxicity while maintaining treatment quality. By carefully monitoring event- and disease-free survival rates, as well as minimal residual disease responses, the trial aims to improve the standard of care for ALL and improve both survival outcomes and patient quality of life.

    BelgiumDenmarkFinlandFranceGermanyNetherlandsNorwayPortugalSwedenUnited Kingdom
  • Exploring sacituzumab govitecan for HER2-negative breast cancer care

    This study is evaluating a new treatment for patients with a certain type of breast cancer (HER2-negative) who have not had a complete response to initial chemotherapy. Participants are randomly assigned to receive the investigational drug sacituzumab govitecan or a treatment of their physician’s choice, which may be another type of chemotherapy with capecitabinalub, carboplatin or cisplatin. The study is designed to compare the effectiveness of these approaches in preventing cancer recurrence. Patients may also receive hormone therapy if needed. Patients’ safety and response to treatment are being closely monitored throughout the study.

    AustriaBelgiumFranceGermanyItalySpain
  • Testing a new drug for skin lupus treatment

    This clinical trial aims to test and gather data on the efficacy of a new drug, BIIB059 (litifilimab), in treating active subacute cutaneous lupus erythematosus (SCLE) and chronic cutaneous lupus erythematosus (CCLE). The trial is specifically for patients who have unsuccessfully tried, or experienced intolerance to, antimalarial treatments. Along with assessing the reduction in the patient’s skin disease activity, the trial will evaluate safety, tolerability, and immunogenicity of BIIB059. Both SCLE and CCLE patients with or without systemic manifestations can participate. The trial involves blind testing and consists of injecting BIIB059 or a placebo to the participants once every four weeks.

    BulgariaFranceGermanyHungaryItalyPolandPortugalSlovakiaSpainSwedenUnited Kingdom
  • Safety and efficacy study of lebrikizumab for atopic dermatitis in children and adolescents

    A clinical trial to test the safety and efficacy of a drug called lebrikizumab in children and adolescents suffering from moderate to severe atopic dermatitis, commonly known as eczema. The study involves participants between the ages of 6 months and 18 years to monitor how well their bodies absorb the drug. Participants receive a saturating dose of the drug, followed by subsequent doses. The number of doses depends on the participant’s weight. The study also includes a control group that will receive a placebo. The effect of the treatment will be measured by various tests, such as the severity index, itch score and quality of life index.

    CzechiaFranceGermanyPolandSpain

See more clinical trials in other cities in Germany:

.